US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof

Case summary

The case is for application US 19/664,540. Its prior art date is 2020-04-10, the earliest priority date. It has 17 claims, as published, 2026-11-05. Claim 1 is independent. The claims have 14 features, by kind: SEQ ID (14). The listing, “us20260347484a1-listing.xml”, holds 20 sequences: 19 protein sequences of 107 to 1,337 residues and 1 DNA sequence of 66 bases. Organisms, with how many sequences name each: synthetic construct (20). The listing is the copy in a weekly full-text file, so it was not checked against WIPO ST.26. The claims recite SEQ ID NOs: 6-7, 10-11 and 14-17. SEQ ID NO: 6 (protein, 112 residues, synthetic construct) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 7 (protein, 117 residues, synthetic construct) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 10 (protein, 107 residues, synthetic construct) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 11 (protein, 125 residues, synthetic construct) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 14 (protein, 112 residues, synthetic construct) is recited in claim 1, and the description cites it in 3 paragraphs. Plan version 1, locked on 2026-11-23, has 1 group: SEQ ID NOs: 6-7, 10-11 and 14-17 on Patent proteins and Swiss-Prot (2 searches). Every kept feature has a search. Plan version 1 ran: 2 of 2 search jobs done.

Filled in from template conductbiology.summaries.template.case.v1 b65b47e0. Accepted by the examiner, ConductScience, 2026-11-23 23:22 UTC.

Case	US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof
Case ID	`8655580a-ff97-46f6-899e-c4fd590a7e0e`
Started	2026-11-23 23:17 UTC by ConductScience
Application	US 19/664,540
Prior art date	2020-04-10 (earliest priority date)
Searches	2: 2 run from the plan, 0 added
Chosen results	5 publications and 0 matches kept
Notes	0
Case log	52 events; every event checks out
Last log event	Event 52, 2026-11-23 23:23 UTC
Last event SHA-256	`faa8e29f00c72d1a11687a044199b80570190eb58c4b7e86f41f7783b4d9dc4c`

Each search below names its record fingerprint: the SHA-256 that Sequences computed over the search record when the search finished. Opened in Sequences, the search shows the same value as recordSha256 under Search record. Any change to the record would change it.

Claims and plan

Claims	17 claims from US 20260347484 A1, imported 2026-11-23 23:17 UTC

Claims SHA-256	`31097796e595f3ef7e41528a52c66d55bef6f6d77301a28a5306321cee42b548`
Claim set	Set 1, as published, 2026-11-05, from US 20260347484 A1, publication XML
Features	14: 14 accepted
Plan	Version 1, locked 2026-11-23 23:17 UTC, 2 searches
Plan SHA-256	`f778d6703edb3dd578dfe6f1958d990c53d2df58c753a26b3f51686068c76521`
Plan follows	Set 1, as published, 2026-11-05, from US 20260347484 A1, publication XML, the current set
Its claims SHA-256	`31097796e595f3ef7e41528a52c66d55bef6f6d77301a28a5306321cee42b548`

The plan's searches

Plan version 1, locked 2026-11-23 23:17 UTC by ConductScience. Plan SHA-256 f778d6703edb3dd578dfe6f1958d990c53d2df58c753a26b3f51686068c76521. Each search runs as written here.

The plan follows set 1, as published, 2026-11-05, from US 20260347484 A1, publication XML. Claims SHA-256 31097796e595f3ef7e41528a52c66d55bef6f6d77301a28a5306321cee42b548.

Search	Query	Method	Set	Thresholds	Reason
P1	SEQ ID NOs: 6 to 7, 10 to 11, 14 to 17 from the listing	Automatic	Patent proteins, snapshot 2026-11-13-5e447c75c43f	Published before 2020-04-10	SEQ ID NOs: 6 to 7, 10 to 11, 14 to 17, in claims 1 and 2: as written.
P2	SEQ ID NOs: 6 to 7, 10 to 11, 14 to 17 from the listing	Automatic	Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21	Published before 2020-04-10	SEQ ID NOs: 6 to 7, 10 to 11, 14 to 17, in claims 1 and 2: as written.

Features no search covered

Every kept feature had a search when this version was locked.

Notes

This case has no notes.

Searches

#	Search	In the case	Finished (UTC)	Matches	Kept
1	US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P1: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17	Plan 1, P1	2026-11-23 23:20	40,000	5
2	US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P2: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17	Plan 1, P2	2026-11-23 23:20	3,112	0

By applicant

The publications a reviewer kept, and the publications that hold each kept match, by the first applicant each publication names. Spellings that differ only in case, accents, punctuation or an ending such as Inc or GmbH share a row, as do names joined in the Applicants tab, with the joins in force when this report was made. Rows go by earliest date, then name, with Applicant not given last.

Applicant	Publications	Earliest	Searches
PFIZER (US)	WO 02053596-A2, 2002-07-11	2002-07-11	1
PIERRE FABRE MEDICAMENT (FR)	WO 03059951-A2, 2003-07-24	2003-07-24	1
Bruce D. Cohen	US 20040086503-A1, 2004-05-06	2004-05-06	1
Liliane Goetsch	US 20050084906-A1, 2005-04-21	2005-04-21	1
VOYAGER THERAPEUTICS, INC.	US 20190153471-A1, 2019-05-23	2019-05-23	1

Summaries

Sequences filled in each summary below from a fixed template, with facts it read from this case. The examiner accepted each one as written, or edited it into their own words, and each row says which. Summaries the examiner rejected are not printed. The case log records every decision.

The results

The case's searches found 50,931 references. 28,640 of them meet the threshold of a claim feature. 23,187 of them were published before the prior art date, 2020-04-10. 10,486 more were filed before that date and published later. 1 of them has no publication date. The top references: US 20190153471-A1 (rank 1, meets F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13 and F14); WO 02053596-A2 (rank 2, meets F2, F5, F9 and F10); WO 03059951-A2 (rank 3, meets F3, F6, F11 and F12); US 20100074900-A1 (rank 4, meets F2, F5, F9 and F10); US 20050226876-A1 (rank 5, meets F13 and F14). Every claim feature has a reference that meets its threshold. They come from searches 1 and 2 from the plan.

Filled in from template conductbiology.summaries.template.results.v1 91ed1f45. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

What the description says about each claimed SEQ ID NO

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 6	SEQ ID NO: 6 is recited in claim 1. Claim 1 recites “SEQ ID NO:6” (threshold as written: identical over the full query) and “SEQ ID NO:6” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0010]: “The light chain variable region (VL) of the antibody is any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14.” Paragraph [0018]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:6 and SEQ ID NO:7 as VL and VH.” Paragraph p-0052: “PHP1003-3 light chain VL: SEQ ID NO: 6, CL: SEQ ID NO: 16”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 7	SEQ ID NO: 7 is recited in claim 1. Claim 1 recites “SEQ ID NO:7” (threshold as written: identical over the full query) and “SEQ ID NO:7” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0013]: “The heavy chain variable region (VH) of the antibody is any one of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15.” Paragraph [0018]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:6 and SEQ ID NO:7 as VL and VH.” Paragraph p-0052: “PHP1003-3 heavy chain VH: SEQ ID NO: 7, CH: SEQ ID NO: 17”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.
SEQ ID NO: 10	SEQ ID NO: 10 is recited in claim 1. Claim 1 recites “SEQ ID NO:10” (threshold as written: identical over the full query) and “SEQ ID NO:10” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0010]: “The light chain variable region (VL) of the antibody is any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14.” Paragraph [0020]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:10 and SEQ ID NO:11 as VL and VH.” Paragraph p-0052: “PHP1003-5 light chain VL: SEQ ID NO: 10, CL: SEQ ID NO: 16”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.
SEQ ID NO: 11	SEQ ID NO: 11 is recited in claim 1. Claim 1 recites “SEQ ID NO:11” (threshold as written: identical over the full query) and “SEQ ID NO:11” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0013]: “The heavy chain variable region (VH) of the antibody is any one of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15.” Paragraph [0020]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:10 and SEQ ID NO:11 as VL and VH.” Paragraph p-0052: “PHP1003-5 heavy chain VH: SEQ ID NO: 11, CH: SEQ ID NO: 17”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.
SEQ ID NO: 14	SEQ ID NO: 14 is recited in claim 1. Claim 1 recites “SEQ ID NO:14” (threshold as written: identical over the full query) and “SEQ ID NO:14” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0010]: “The light chain variable region (VL) of the antibody is any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14.” Paragraph [0022]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:14 and SEQ ID NO:15 as VL and VH.” Paragraph p-0052: “PHP1003-7 light chain VL: SEQ ID NO: 14, CL: SEQ ID NO: 16”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.
SEQ ID NO: 15	SEQ ID NO: 15 is recited in claim 1. Claim 1 recites “SEQ ID NO:15” (threshold as written: identical over the full query) and “SEQ ID NO:15” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0013]: “The heavy chain variable region (VH) of the antibody is any one of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15.” Paragraph [0022]: “In some embodiments, the invention provides an antibody comprising SEQ ID NO:14 and SEQ ID NO:15 as VL and VH.” Paragraph p-0052: “PHP1003-7 heavy chain VH: SEQ ID NO: 15, CH: SEQ ID NO: 17”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.
SEQ ID NO: 16	SEQ ID NO: 16 is recited in claim 2. Claim 2 recites “SEQ ID NO:16” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0011]: “In some embodiments, the invention provides an antibody whose light chain constant region (CL) is SEQ ID NO:16.” Paragraph [0012]: “In some embodiments, the invention provides an antibody whose light chain comprises the light chain variable region and the light chain constant region shown in SEQ ID no: 16.” Paragraph p-0052: “PHP1003-1 light chain VL: SEQ ID NO: 2, CL: SEQ ID NO: 16”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 17	SEQ ID NO: 17 is recited in claim 2. Claim 2 recites “SEQ ID NO:17” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0014]: “In some embodiments, the invention provides an antibody whose heavy chain constant region (CH) is SEQ ID NO:17.” Paragraph [0015]: “In some embodiments, the invention provides an antibody whose heavy chain of comprises the heavy chain variable region and the heavy chain constant region shown in SEQ ID NO:17.” Paragraph p-0052: “PHP1003-1 heavy chain VH: SEQ ID NO: 3, CH: SEQ ID NO: 17”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

The searches

A search's summary describes what the search returned, before the examiner's marks. Each search's section below shows the marks.

Search	Summary	Filled in, then accepted by the examiner
Search 1	Search 1, “US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P1: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17”, came from plan version 1, search P1. Method: Automatic (Smith-Waterman). Data searched: Public patent sequences and US applications: Patent proteins, snapshot 2026-11-13-5e447c75c43f, sources to 2026-11-13. Filters: published before 2020-04-10. Engine settings: tool: ssearch36; query: protein. It ran 8 queries and returned 40,000 hits. For feature F1 of claim 1 (“SEQ ID NO:6”, threshold as written: identical over the full query), it found 8,199 references. The first 5 in rank order: US 20190153471-A1, US 20190192691-A1, US 20200023076-A1, US 20210261649-A1 and US 11326182-B2. US 20190153471-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2019-05-23, before the prior art date; Query Match 100.0%; E-value 4.40e-41. For feature F2 of claim 1 (“SEQ ID NO:10”, threshold as written: identical over the full query), it found 10,071 references. The first 5 in rank order: WO 02053596-A2, KR 1020037009063-A, US 20040086503-A1, WO 2004071529-A2 and JP 2004531217-A. WO 02053596-A2 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2002-07-11, before the prior art date; Query Match 100.0%; E-value 9.20e-31. For feature F3 of claim 1 (“SEQ ID NO:14”, threshold as written: identical over the full query), it found 8,439 references. The first 5 in rank order: WO 03059951-A2, US 20050084906-A1, WO 2005058967-A2, US 20050249730-A1 and JP 2005536181-A. WO 03059951-A2 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2003-07-24, before the prior art date; Query Match 100.0%; E-value 9.00e-33. For feature F4 of claim 1 (“SEQ ID NO:7”, threshold as written: identical over the full query), it found 6,225 references. The first 5 in rank order: US 20190153471-A1, US 20190192691-A1, US 20200023076-A1, US 20210261649-A1 and US 11326182-B2. US 20190153471-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2019-05-23, before the prior art date; Query Match 100.0%; E-value 4.30e-48. For feature F5 of claim 1 (“SEQ ID NO:11”, threshold as written: identical over the full query), it found 7,007 references. The first 5 in rank order: US 20100074900-A1, US 20100076178-A1, WO 2010036767-A1, US 20100120090-A1 and WO 2010056816-A1. US 20100074900-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-03-25, before the prior art date; Query Match 100.0%; E-value 3.40e-38. It served more claim features than this summary has room for; the References step lists them all.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

Search	Summary	Filled in, then accepted by the examiner
Search 2	Search 2, “US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P2: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17”, came from plan version 1, search P2. Method: Automatic (Smith-Waterman). Data searched: Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21, sources to 2026-11-10. Filters: published before 2020-04-10. Engine settings: tool: ssearch36; query: protein. It ran 8 queries and returned 3,112 hits. For feature F1 of claim 1 (“SEQ ID NO:6”, threshold as written: identical over the full query), it found 384 references. The first 5 in rank order: P01631, P01630, P03976, P01629 and P01618. P01631 ranks first. Rank keys, in order: not as written (75.0% identity over the full query); coverage of the claimed region 100.0%; published 1983, before the prior art date; Query Match 72.4%; E-value 3.30e-49. For feature F2 of claim 1 (“SEQ ID NO:10”, threshold as written: identical over the full query), it found 485 references. The first 5 in rank order: P0DOX7, P01652, P01650, P01653 and P01644. P0DOX7 ranks first. Rank keys, in order: not as written (78.5% identity over the full query); coverage of the claimed region 100.0%; published 1970, before the prior art date; Query Match 75.4%; E-value 2.90e-46. For feature F3 of claim 1 (“SEQ ID NO:14”, threshold as written: identical over the full query), it found 485 references. The first 5 in rank order: P01631, P01630, P03976, P01629 and P01618. P01631 ranks first. Rank keys, in order: not as written (81.3% identity over the full query); coverage of the claimed region 100.0%; published 1983, before the prior art date; Query Match 81.0%; E-value 4.60e-53. For feature F4 of claim 1 (“SEQ ID NO:7”, threshold as written: identical over the full query), it found 287 references. The first 5 in rank order: P0DOX3, P01823, P01819, P01811 and P01808. P0DOX3 ranks first. Rank keys, in order: not as written (64.1% identity over the full query); coverage of the claimed region 100.0%; published 1982, before the prior art date; Query Match 54.6%; E-value 1.70e-36. For feature F5 of claim 1 (“SEQ ID NO:11”, threshold as written: identical over the full query), it found 419 references. The first 5 in rank order: P0DOX2, P01788, P01787, P01794 and P01790. P0DOX2 ranks first. Rank keys, in order: not as written (72.8% identity over the full query); coverage of the claimed region 100.0%; published 1977, before the prior art date; Query Match 68.1%; E-value 1.70e-47. For feature F6 of claim 1 (“SEQ ID NO:15”, threshold as written: identical over the full query), it found 442 references. The first 5 in rank order: P01823, P0DOX3, P01819, P01811 and P01808. P01823 ranks first. Rank keys, in order: not as written (65.8% identity over the full query); coverage of the claimed region 100.0%; published 1983, before the prior art date; Query Match 62.0%; E-value 1.10e-41. It served more claim features than this summary has room for; the References step lists them all.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:23 UTC.

Claim charts

Each chart sets a claim's features against one reference. Fixed rules (claim charts 1.0.0) read each feature against the reference's best match in this case's searches: Met, Not met, or Not shown where the match does not show it. Where the examiner set an answer, the chart gives it with the rule's answer beside it and the examiner's note. The case log records every answer. In a patent's table, What the patent says quotes a US publication's own words on its matching SEQ ID NOs, word for word, with where each comes from, or says why there is no quote (fixed rules, quotes 1.0.0).

Claim 1 and US 20190153471-A1

COMPOSITIONS FOR THE TREATMENT OF DISEASE. Published 2019-05-23, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 3200, 3201, 3202, 3234, 3241, 3255, 3859, 3861, 3862, 3876, 3877, 3879, 3888, 3899, 3902, 3976, 3994, 4052, 4054 and 4055, and 91 more. Source: Row 3 of search 1, US 20190153471-A1	Claim 1: “… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof.” Claim 15: “The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof.” SEQ ID NO: 3200 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3201 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3202 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6.
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 3265, 4451, 4454, 4530, 7645, 7655, 7707, 7864, 8107, 8387, 8388, 8389, 8390, 8449, 8453, 8481, 8533, 8710, 8713 and 8754, and 188 more. Source: Row 10,001 of search 1, US 20190153471-A1	Claim 1: “… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof.” Claim 15: “The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof.” SEQ ID NO: 3265 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013] and [0287] and the text after [0287], the first 3 places of 16. SEQ ID NO: 4451 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0290] and [0510], the first 3 places of 7. SEQ ID NO: 4454 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0290] and [0510], the first 3 places of 7.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 3200, 3202, 3234, 3255, 3859, 3861, 3862, 3876, 3877, 3879, 3888, 3899, 3902, 3976, 3994, 4052, 4054, 4055, 4056 and 4057, and 95 more. Source: Row 20,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3200 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3202 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3234 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6.
SEQ ID NO:7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 3025, 3168, 3468, 4250, 4676, 4710, 4723, 4954, 5014, 5019, 5025, 6602, 7049, 10414, 10478, 10494, 10709, 10710, 10730 and 10731, and 67 more. Source: Row 5,003 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3025 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3168 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 20. SEQ ID NO: 3468 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 1 to 125 of its sequence. Its SEQ ID NOs: 3113, 3115, 3122, 3689, 3690, 3756, 4249, 4314, 4493, 4947, 4958, 5017, 5162, 5164, 5465, 5479, 5528, 5550, 6331 and 6408, and 75 more. Source: Row 15,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3113 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3115 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3122 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14.
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 3025, 3468, 4250, 4676, 4954, 5014, 5019, 7049, 10414, 10478, 10709, 10730, 10731, 10732, 10733, 10992, 11227, 11228, 11230 and 11232, and 61 more. Source: Row 25,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3025 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3468 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7. SEQ ID NO: 4250 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 3200, 3201, 3202, 3234, 3241, 3255, 3859, 3861, 3862, 3876, 3877, 3879, 3888, 3899, 3902, 3976, 3994, 4052, 4054 and 4055, and 91 more. Source: Row 3 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3200 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3201 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3202 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6.
SEQ ID NO:7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 3025, 3168, 3468, 4250, 4676, 4710, 4723, 4954, 5014, 5019, 5025, 6602, 7049, 10414, 10478, 10494, 10709, 10710, 10730 and 10731, and 67 more. Source: Row 5,003 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3025 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3168 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 20. SEQ ID NO: 3468 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 3265, 4451, 4454, 4530, 7645, 7655, 7707, 7864, 8107, 8387, 8388, 8389, 8390, 8449, 8453, 8481, 8533, 8710, 8713 and 8754, and 188 more. Source: Row 10,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3265 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013] and [0287] and the text after [0287], the first 3 places of 16. SEQ ID NO: 4451 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0290] and [0510], the first 3 places of 7. SEQ ID NO: 4454 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0290] and [0510], the first 3 places of 7.
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 1 to 125 of its sequence. Its SEQ ID NOs: 3113, 3115, 3122, 3689, 3690, 3756, 4249, 4314, 4493, 4947, 4958, 5017, 5162, 5164, 5465, 5479, 5528, 5550, 6331 and 6408, and 75 more. Source: Row 15,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3113 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3115 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3122 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 3200, 3202, 3234, 3255, 3859, 3861, 3862, 3876, 3877, 3879, 3888, 3899, 3902, 3976, 3994, 4052, 4054, 4055, 4056 and 4057, and 95 more. Source: Row 20,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3200 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3202 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6. SEQ ID NO: 3234 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0290], the first 3 places of 6.
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 3025, 3468, 4250, 4676, 4954, 5014, 5019, 7049, 10414, 10478, 10709, 10730, 10731, 10732, 10733, 10992, 11227, 11228, 11230 and 11232, and 61 more. Source: Row 25,001 of search 1, US 20190153471-A1	Claim 1: "… (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides selected from the group consisting of SEQ ID NO: 2948-17938, and fragments thereof." Claim 15: "The AAV particle of claim 14, wherein the first nucleic acid segment encodes one or more antibody heavy chains selected from SEQ ID NO: 2948-17938, and fragments thereof." SEQ ID NO: 3025 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0287] and [0289], the first 3 places of 14. SEQ ID NO: 3468 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7. SEQ ID NO: 4250 is named in claims 1, 15, 17, 20, 21 and 22 and in paragraphs [0013], [0289] and [0290], the first 3 places of 7.

Claim 1 and WO 02053596-A2

Antibodies to insulin-like growth factor I receptor. Published 2002-07-11, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Not shown	No match under this feature	
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 6, 10, 14, 40, 47, 48, 51 and 52. Source: Row 10,001 of search 1, WO 02053596-A2	Quotes come from the full text of US publications only.
SEQ ID NO:14	Not shown	No match under this feature	
SEQ ID NO:7	Not shown	No match under this feature	

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 20 to 144 of its sequence. Its SEQ ID NOs: 8, 16, 45, 46 and 50. Source: Row 15,033 of search 1, WO 02053596-A2	Quotes come from the full text of US publications only.
SEQ ID NO:15	Not shown	No match under this feature	
SEQ ID NO:6	Not shown	No match under this feature	
SEQ ID NO:7	Not shown	No match under this feature	
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 6, 10, 14, 40, 47, 48, 51 and 52. Source: Row 10,001 of search 1, WO 02053596-A2	Quotes come from the full text of US publications only.
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 20 to 144 of its sequence. Its SEQ ID NOs: 8, 16, 45, 46 and 50. Source: Row 15,033 of search 1, WO 02053596-A2	Quotes come from the full text of US publications only.
SEQ ID NO:14	Not shown	No match under this feature	
SEQ ID NO:15	Not shown	No match under this feature	

Claim 1 and US 20040086503-A1

Antibodies to insulin-like growth factor I receptor. Published 2004-05-06, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Not shown	No match under this feature	
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 6, 10, 14, 40, 47, 48, 51 and 52. Source: Row 10,001 of search 1, US 20040086503-A1	Claim 9: “… light chain comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18 and SEQ ID NO: 22, or an amino acid sequence having 1-10 amino acid insertions, deletions or substitutions therefrom.” Claim 13: “… b) a variable region of a light chain comprising an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18 and SEQ ID NO: 22, or an amino acid sequence having 1-10 amino acid insertions, deletions or substitutions therefrom; …” SEQ ID NO: 6 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 10 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 14 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:14	Not shown	No match under this feature	
SEQ ID NO:7	Not shown	No match under this feature	
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 20 to 144 of its sequence. Its SEQ ID NOs: 8, 16, 45, 46 and 50. Source: Row 15,033 of search 1, US 20040086503-A1	Claim 11: "… region of the heavy chain comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20 and SEQ ID NO: 24, or an amino acid sequence having 1-10 amino acid insertions, deletions or …" Claim 16: "… c) the amino acid sequence of SEQ ID NO: 45 and the amino acid sequence of SEQ ID NO: 47; …" SEQ ID NO: 8 is named in claims 11, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 16 is named in claims 11, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 45 is named in claim 16 and in paragraph [0032].
SEQ ID NO:15	Not shown	No match under this feature	
SEQ ID NO:6	Not shown	No match under this feature	
SEQ ID NO:7	Not shown	No match under this feature	
SEQ ID NO:10	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 10 positions 1 to 107 align with positions 1 to 107 of its sequence. Its SEQ ID NOs: 6, 10, 14, 40, 47, 48, 51 and 52. Source: Row 10,001 of search 1, US 20040086503-A1	Claim 9: "… light chain comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18 and SEQ ID NO: 22, or an amino acid sequence having 1-10 amino acid insertions, deletions or substitutions therefrom." Claim 13: "… b) a variable region of a light chain comprising an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18 and SEQ ID NO: 22, or an amino acid sequence having 1-10 amino acid insertions, deletions or substitutions therefrom; …" SEQ ID NO: 6 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 10 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 14 is named in claims 9, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:11	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 11 positions 1 to 125 align with positions 20 to 144 of its sequence. Its SEQ ID NOs: 8, 16, 45, 46 and 50. Source: Row 15,033 of search 1, US 20040086503-A1	Claim 11: "… region of the heavy chain comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20 and SEQ ID NO: 24, or an amino acid sequence having 1-10 amino acid insertions, deletions or …" Claim 16: "… c) the amino acid sequence of SEQ ID NO: 45 and the amino acid sequence of SEQ ID NO: 47; …" SEQ ID NO: 8 is named in claims 11, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 16 is named in claims 11, 13, 14 and 28 and in paragraphs [0091], [0099] and [0100], the first 3 places of 11. SEQ ID NO: 45 is named in claim 16 and in paragraph [0032].
SEQ ID NO:14	Not shown	No match under this feature	
SEQ ID NO:15	Not shown	No match under this feature	

Claim 1 and WO 03059951-A2

Novel anti-IGF-IR antibodies and uses thereof. Published 2003-07-24, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Not met	Not as written: 91.1% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 5 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:10	Not shown	No match under this feature	
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 20,001 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:7	Not met	Not as written: 89.7% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 72, 73, 75, 77, 79, 81, 83 and 85. Source: Row 5,005 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:11	Not shown	No match under this feature	
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 70, 75, 77, 79, 81, 83 and 85. Source: Row 25,001 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Not met	Not as written: 91.1% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 5 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:7	Not met	Not as written: 89.7% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 72, 73, 75, 77, 79, 81, 83 and 85. Source: Row 5,005 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:10	Not shown	No match under this feature	
SEQ ID NO:11	Not shown	No match under this feature	
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 20,001 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 70, 75, 77, 79, 81, 83 and 85. Source: Row 25,001 of search 1, WO 03059951-A2	Quotes come from the full text of US publications only.

Claim 1 and US 20050084906-A1

Novel anti-IGF-IR antibodies and uses thereof. Published 2005-04-21, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:6	Not met	Not as written: 91.1% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 5 of search 1, US 20050084906-A1	Claim 11: “… its functional fragments, as claimed in claim 1, wherein said antibody comprises a light chain of sequence comprising the amino acid sequence SEQ ID No. 54, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain …” Paragraph [0270]: “FIG. 14: Sequence of the cDNA (SEQ ID No. 48), of its complementary strand (SEQ ID No. 50) and its translation into amino acids (SEQ ID No. 49), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MKV-1 and MKC and which codes for the 3' end of the loader peptide and 7C10 …” SEQ ID NO: 49 is named in paragraphs [0270] and [0372]. SEQ ID NO: 54 is named in claim 11 and in paragraphs [0043], [0273] and [0275], the first 3 places of 6. SEQ ID NO: 55 is named in paragraphs [0274] and [0383].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:10	Not shown	No match under this feature	
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 20,001 of search 1, US 20050084906-A1	Claim 11: "… its functional fragments, as claimed in claim 1, wherein said antibody comprises a light chain of sequence comprising the amino acid sequence SEQ ID No. 54, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain …" Paragraph [0270]: "FIG. 14: Sequence of the cDNA (SEQ ID No. 48), of its complementary strand (SEQ ID No. 50) and its translation into amino acids (SEQ ID No. 49), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MKV-1 and MKC and which codes for the 3' end of the loader peptide and 7C10 …" SEQ ID NO: 49 is named in paragraphs [0270] and [0372]. SEQ ID NO: 54 is named in claim 11 and in paragraphs [0043], [0273] and [0275], the first 3 places of 6. SEQ ID NO: 55 is named in paragraphs [0274] and [0383].
SEQ ID NO:7	Not met	Not as written: 89.7% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 72, 73, 75, 77, 79, 81, 83 and 85. Source: Row 5,005 of search 1, US 20050084906-A1	Claim 11: "… a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain of sequence comprising the amino acid sequence SEQ ID No. 69, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 69." Paragraph [0271]: "FIG. 15: Sequence of the cDNA (SEQ ID No. 51), of its complementary strand (SEQ ID No. 53) and its translation into amino acids (SEQ ID No. 52), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MHV-12 and MHC-1, or MHV-8 and MHC-1 and which codes for the 3' end of the …" SEQ ID NO: 52 is named in paragraphs [0271] and [0376]. SEQ ID NO: 69 is named in claim 11 and in paragraphs [0043], [0281] and [0283], the first 3 places of 6. SEQ ID NO: 72 is named in paragraphs [0283] and [0401].
SEQ ID NO:11	Not shown	No match under this feature	

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 70, 75, 77, 79, 81, 83 and 85. Source: Row 25,001 of search 1, US 20050084906-A1	Claim 11: "… a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain of sequence comprising the amino acid sequence SEQ ID No. 69, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 69." Paragraph [0271]: "FIG. 15: Sequence of the cDNA (SEQ ID No. 51), of its complementary strand (SEQ ID No. 53) and its translation into amino acids (SEQ ID No. 52), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MHV-12 and MHC-1, or MHV-8 and MHC-1 and which codes for the 3' end of the …" SEQ ID NO: 52 is named in paragraphs [0271] and [0376]. SEQ ID NO: 69 is named in claim 11 and in paragraphs [0043], [0281] and [0283], the first 3 places of 6. SEQ ID NO: 70 is named in paragraphs [0282] and [0394].
SEQ ID NO:6	Not met	Not as written: 91.1% identity over the full query. SEQ ID NO: 6 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 5 of search 1, US 20050084906-A1	Claim 11: "… its functional fragments, as claimed in claim 1, wherein said antibody comprises a light chain of sequence comprising the amino acid sequence SEQ ID No. 54, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain …" Paragraph [0270]: "FIG. 14: Sequence of the cDNA (SEQ ID No. 48), of its complementary strand (SEQ ID No. 50) and its translation into amino acids (SEQ ID No. 49), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MKV-1 and MKC and which codes for the 3' end of the loader peptide and 7C10 …" SEQ ID NO: 49 is named in paragraphs [0270] and [0372]. SEQ ID NO: 54 is named in claim 11 and in paragraphs [0043], [0273] and [0275], the first 3 places of 6. SEQ ID NO: 55 is named in paragraphs [0274] and [0383].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:7	Not met	Not as written: 89.7% identity over the full query. SEQ ID NO: 7 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 72, 73, 75, 77, 79, 81, 83 and 85. Source: Row 5,005 of search 1, US 20050084906-A1	Claim 11: "… a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain of sequence comprising the amino acid sequence SEQ ID No. 69, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 69." Paragraph [0271]: "FIG. 15: Sequence of the cDNA (SEQ ID No. 51), of its complementary strand (SEQ ID No. 53) and its translation into amino acids (SEQ ID No. 52), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MHV-12 and MHC-1, or MHV-8 and MHC-1 and which codes for the 3' end of the …" SEQ ID NO: 52 is named in paragraphs [0271] and [0376]. SEQ ID NO: 69 is named in claim 11 and in paragraphs [0043], [0281] and [0283], the first 3 places of 6. SEQ ID NO: 72 is named in paragraphs [0283] and [0401].
SEQ ID NO:10	Not shown	No match under this feature	
SEQ ID NO:11	Not shown	No match under this feature	
SEQ ID NO:14	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 14 positions 1 to 112 align with positions 1 to 112 of its sequence. Its SEQ ID NOs: 49, 54, 55, 56, 57, 61, 63, 65 and 67. Source: Row 20,001 of search 1, US 20050084906-A1	Claim 11: "… its functional fragments, as claimed in claim 1, wherein said antibody comprises a light chain of sequence comprising the amino acid sequence SEQ ID No. 54, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain …" Paragraph [0270]: "FIG. 14: Sequence of the cDNA (SEQ ID No. 48), of its complementary strand (SEQ ID No. 50) and its translation into amino acids (SEQ ID No. 49), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MKV-1 and MKC and which codes for the 3' end of the loader peptide and 7C10 …" SEQ ID NO: 49 is named in paragraphs [0270] and [0372]. SEQ ID NO: 54 is named in claim 11 and in paragraphs [0043], [0273] and [0275], the first 3 places of 6. SEQ ID NO: 55 is named in paragraphs [0274] and [0383].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO:15	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 15 positions 1 to 117 align with positions 1 to 117 of its sequence. Its SEQ ID NOs: 52, 69, 70, 75, 77, 79, 81, 83 and 85. Source: Row 25,001 of search 1, US 20050084906-A1	Claim 11: "… a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 54, or/and in that it comprises a heavy chain of sequence comprising the amino acid sequence SEQ ID No. 69, or a sequence having at least 80% identity after optimum alignment with the sequence SEQ ID No. 69." Paragraph [0271]: "FIG. 15: Sequence of the cDNA (SEQ ID No. 51), of its complementary strand (SEQ ID No. 53) and its translation into amino acids (SEQ ID No. 52), of the PCR fragment amplified from the mouse hybridoma 7C10 with the primers MHV-12 and MHC-1, or MHV-8 and MHC-1 and which codes for the 3' end of the …" SEQ ID NO: 52 is named in paragraphs [0271] and [0376]. SEQ ID NO: 69 is named in claim 11 and in paragraphs [0043], [0281] and [0283], the first 3 places of 6. SEQ ID NO: 70 is named in paragraphs [0282] and [0394].

Search 1: US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P1: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17

Search ID	`41607d0f-cfdf-40cf-987c-bff9a969cf33`
In this case	Run from plan version 1, search P1, by ConductScience on 2026-11-23 23:17 UTC
Finished	2026-11-23 23:20 UTC
Data searched	Public patent sequences and US applications: Patent proteins (17,651,841 sequences, 2,420,942,521 letters)
Data version	Snapshot 2026-11-13-5e447c75c43f, set patent_prot, sources to 2026-11-13, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2020-04-10, as the plan set
Query fingerprint	`18c690e0777a42fda5d3ac2d2d8e97856617ae64433e1c9496181f991493f607`
Record fingerprint	`4d73a0db17f8a3e949ad91031b6b9daea232d4c42e873b2987e2f6f7327d362d`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_6	112		5,000	Yes
SEQ_ID_NO_7	117		5,000	Yes
SEQ_ID_NO_10	107		5,000	Yes
SEQ_ID_NO_11	125		5,000	Yes
SEQ_ID_NO_14	112		5,000	Yes
SEQ_ID_NO_15	117		5,000	Yes
SEQ_ID_NO_16	107		5,000	Yes
SEQ_ID_NO_17	330		5,000	Yes

```
>SEQ_ID_NO_6  (112 letters)
      1  DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNGNTWLQW WLQKPGQSPQ LLIWKVSNRL
     61  WGVPDRFSGS GSGTDFTLKI SRVQAQDVGV WWCFQGSHVP WTFGQGTKVQ IK

>SEQ_ID_NO_7  (117 letters)
      1  QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG WISWDGTNNW
     61  KPSLKDRVTI SVDTSKNQFS LKLSSVTAAD TAVWWCARWG RVFFDWWGQG TLVTVSS

>SEQ_ID_NO_10  (107 letters)
      1  DIQMTQFPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASRLHRGVPS
     61  RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPCSFGQ GTKLEIK

>SEQ_ID_NO_11  (125 letters)
      1  EVQLLESGGG LVQPGGSLRL SCTASGFTFS SYAMNWVRQA PGKGLEWVSA ISGSGGTTFY
     61  ADSVKGRFTI SRDNSRTTLY LQMNSLRAED TAVYYCAKDL GWSDSYYYYY GMDVWGQGTT
    121  VTVSS

>SEQ_ID_NO_14  (112 letters)
```

```
      1  DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSNGNTYLQW YLQKPGQSPQ LLIYKVSNRL
     61  YGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP WTFGQGTKVE IK

>SEQ_ID_NO_15  (117 letters)
      1  QVQLQESGPG LVKPSETLSL TCTVSGYSIT GGYLWNWIRQ PPGKGLEWIG YISYDGTNNY
     61  KPSLKDRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARYG RVFFDYWGQG TLVTVSS

>SEQ_ID_NO_16  (107 letters)
      1  RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD
     61  SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC

>SEQ_ID_NO_17  (330 letters)
      1  ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
     61  GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGG
    121  PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
    181  STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
    241  LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
    301  QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
```

Chosen publications

Publication	Published	Filed	Applicant	Title	Best query match	Reason
WO 02053596-A2	2002-07-11		PFIZER (US)	Antibodies to insulin-like growth factor I receptor	100%	
WO 03059951-A2	2003-07-24		PIERRE FABRE MEDICAMENT (FR)	Novel anti-IGF-IR antibodies and uses thereof	100%	
US 20040086503-A1	2004-05-06	2002-01-04, priority 2001-01-05	Bruce D. Cohen	Antibodies to insulin-like growth factor I receptor	100%	
US 20050084906-A1	2005-04-21	2003-12-16, priority 2002-01-18	Liliane Goetsch	Novel anti-IGF-IR antibodies and uses thereof	100%	
US 20190153471-A1	2019-05-23	2017-04-28, priority 2016-04-29	VOYAGER THERAPEUTICS, INC.	COMPOSITIONS FOR THE TREATMENT OF DISEASE	100%	

Why each chosen publication counts

The sentences a reviewer accepted, or edited into their own words, for each kept publication. Each draft stated one stored fact, and the case log keeps every draft and decision.

Publication	Why it counts	Sources
WO 02053596-A2	SEQ ID NO: 45 of WO 02053596-A2 matches SEQ ID NO: 11 of claim 1 at 100% identity over 125 of 125 residues (Query Match 100%). Published 2002-07-11, before the earliest priority date of 2020-04-10.	Row 15,033 of this search; WO 02053596-A2: https://patents.google.com/patent/WO2002053596A2
WO 03059951-A2	SEQ ID NO: 79 of WO 03059951-A2 matches SEQ ID NO: 15 of claim 1 at 100% identity over 117 of 117 residues (Query Match 100%). Published 2003-07-24, before the earliest priority date of 2020-04-10.	Row 25,001 of this search; WO 03059951-A2: https://patents.google.com/patent/WO2003059951A2
US 20040086503-A1	SEQ ID NO: 45 of US 20040086503-A1 matches SEQ ID NO: 11 of claim 1 at 100% identity over 125 of 125 residues (Query Match 100%). Published 2004-05-06, before the earliest priority date of 2020-04-10.	Row 15,033 of this search; US 20040086503-A1: https://patents.google.com/patent/US20040086503A1

Publication	Why it counts	Sources
US 20050084906-A1	SEQ ID NO: 79 of US 20050084906-A1 matches SEQ ID NO: 15 of claim 1 at 100% identity over 117 of 117 residues (Query Match 100%). Published 2005-04-21, before the earliest priority date of 2020-04-10.	Row 25,001 of this search; US 20050084906-A1: https://patents.google.com/patent/US20050084906A1
US 20190153471-A1	SEQ ID NO: 12611 of US 20190153471-A1 matches SEQ ID NO: 17 of claim 2 at 100% identity over 330 of 330 residues (Query Match 100%). Published 2019-05-23, before the earliest priority date of 2020-04-10.	Row 35,001 of this search; US 20190153471-A1: https://patents.google.com/patent/US20190153471A1

Top publications

The first 15 of 49,922 publications, by best query match.

Publication	Published	Applicant	Title	Best query match	Matches
WO 8902922-A	1989-04-06		ADHESON VARIANTS	100%	2
EP 0314317-A1	1989-05-03		Adheson variants, nucleic acid encoding them and compositions comprising them	100%	2
KR 1019940702179-A	1994-06-20		A humanized antibody specific for the platelet integrin GP2B/3A	100%	2
EP 0737747-A2	1996-10-16	BEHRINGWERKE AG (DE)	Cytoplasmatic expression in E. coli of antibodies, antibody fragments and fusions thereof	100%	1
US 5739277-A	1998-04-14		Altered polypeptides with increased half-life	100%	1
US 5747035-A	1998-05-05		Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor	100%	1
US 5777085-A	1998-07-07		Humanized antibodies reactive with GPIIB/IIIA	100%	2
US 5821337-A	1998-10-13		Immunoglobulin variants	100%	3
US 5869046-A	1999-02-09		Altered polypeptides with increased half-life	100%	1
EP 0953639-A1	1999-11-03	BOEHRINGER INGELHEIM INT (DE)	FAPalpha-specific antibody with improved producibility	100%	1
WO 9957151-A2	1999-11-11	GARIN CHESA PILAR (DE)	Fap alpha -specific antibody with improved producibility	100%	1
US 6008023-A	1999-12-28		Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli	100%	1
US 6129914-A	2000-10-10		Bispecific antibody effective to treat B-cell lymphoma and cell line	100%	2
KR 1020007011585-A	2000-10-18		FAP alpha-specific antibody with improved producibility	100%	1
US 6171586-A	2001-01-09		Antibody formulation	100%	1

Top matches

The first 25 of 22,229 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
30,081	SEQ_ID_NO_16	AAA54095.1	WO 8902922-A	1989-04-06	100%	100%	100%	3.5e-45
33,351	SEQ_ID_NO_16	AAC91400.1	KR 1019940702179-A	1994-06-20	100%	100%	100%	5.1e-45
31,683	SEQ_ID_NO_16	A57360.1	EP 0737747-A2	1996-10-16	100%	100%	100%	5.1e-45
30,001	SEQ_ID_NO_16	A94039.1	US 5739277-A	1998-04-14	100%	100%	100%	2.6e-45
34,638	SEQ_ID_NO_16	AAE23209.1	US 5821337-A	1998-10-13	100%	100%	100%	5.1e-45
34,889	SEQ_ID_NO_16	AAE23208.1	US 5821337-A	1998-10-13	100%	100%	100%	5.1e-45
30,844	SEQ_ID_NO_16	AAE51561.1	US 6129914-A	2000-10-10	100%	100%	100%	5.1e-45
31,490	SEQ_ID_NO_16	BD539030	WO 2001023431-A	2001-04-05	100%	100%	100%	5.1e-45
34,049	SEQ_ID_NO_16	AAS31015.1	KR 1020017007965-A	2001-06-22	100%	100%	100%	5.1e-45
30,682	SEQ_ID_NO_16	AAW13462.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
30,709	SEQ_ID_NO_16	AAW13464.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
30,784	SEQ_ID_NO_16	AAW13478.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
30,893	SEQ_ID_NO_16	AAW13468.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
31,416	SEQ_ID_NO_16	AAW13472.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
31,417	SEQ_ID_NO_16	AAW13466.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
31,561	SEQ_ID_NO_16	AAW13470.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
31,832	SEQ_ID_NO_16	AAW13474.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
31,918	SEQ_ID_NO_16	AAW13476.1	WO 0164751-A2	2001-09-07	100%	100%	100%	5.1e-45
33,931	SEQ_ID_NO_16	AAE88991.1	US 6339142-A	2002-01-15	100%	100%	100%	5.1e-45
30,466	SEQ_ID_NO_16	AAW18744.1	WO 0248376-A2	2002-06-20	100%	100%	100%	5.1e-45
10,001	SEQ_ID_NO_10	ADA36201.1	WO 02053596-A2	2002-07-11	100%	100%	100%	9.2e-31

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
10,025	SEQ_ID_NO_10	ADA36226.1	WO 02053596-A2	2002-07-11	100%	100%	100%	1.6e-30
15,033	SEQ_ID_NO_11	ADA36224.1	WO 02053596-A2	2002-07-11	100%	100%	100%	7.8e-38
30,006	SEQ_ID_NO_16	AEF63769.1	KR 1020020045768-A	2002-08-02	100%	100%	100%	2.6e-45
33,514	SEQ_ID_NO_16	ADS93824.1	WO 02072832-A2	2002-09-19	100%	100%	100%	5.1e-45

Search 2: US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof, plan 1 P2: SEQ ID NO: 6 to 7, 10 to 11, 14 to 17

Search ID	`af01d917-96b9-4eb6-a167-941ddd7a11b3`
In this case	Run from plan version 1, search P2, by ConductScience on 2026-11-23 23:17 UTC
Finished	2026-11-23 23:20 UTC
Data searched	Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot (487,796 sequences, 186,172,811 letters)
Data version	Snapshot 2026-11-10-37cac4ca8f21, set swissprot, sources to 2026-11-10, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2020-04-10, as the plan set
Query fingerprint	`18c690e0777a42fda5d3ac2d2d8e97856617ae64433e1c9496181f991493f607`
Record fingerprint	`7f6c59c902b86883ecf701c0c88ba85a9eca4e03435f23a904120aef072c1721`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_6	112		376	No
SEQ_ID_NO_7	117		281	No
SEQ_ID_NO_10	107		477	No
SEQ_ID_NO_11	125		409	No
SEQ_ID_NO_14	112		477	No
SEQ_ID_NO_15	117		433	No
SEQ_ID_NO_16	107		312	No
SEQ_ID_NO_17	330		347	No

```
>SEQ_ID_NO_6  (112 letters)
      1  DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNGNTWLQW WLQKPGQSPQ LLIWKVSNRL
     61  WGVPDRFSGS GSGTDFTLKI SRVQAQDVGV WWCFQGSHVP WTFGQGTKVQ IK

>SEQ_ID_NO_7  (117 letters)
      1  QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG WISWDGTNNW
     61  KPSLKDRVTI SVDTSKNQFS LKLSSVTAAD TAVWWCARWG RVFFDWWGQG TLVTVSS

>SEQ_ID_NO_10  (107 letters)
      1  DIQMTQFPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASRLHRGVPS
     61  RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPCSFGQ GTKLEIK

>SEQ_ID_NO_11  (125 letters)
      1  EVQLLESGGG LVQPGGSLRL SCTASGFTFS SYAMNWVRQA PGKGLEWVSA ISGSGGTTFY
     61  ADSVKGRFTI SRDNSRTTLY LQMNSLRAED TAVYYCAKDL GWSDSYYYYY GMDVWGQGTT
    121  VTVSS

>SEQ_ID_NO_14  (112 letters)
```

```
      1  DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSNGNTYLQW YLQKPGQSPQ LLIYKVSNRL
     61  YGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP WTFGQGTKVE IK

>SEQ_ID_NO_15  (117 letters)
      1  QVQLQESGPG LVKPSETLSL TCTVSGYSIT GGYLWNWIRQ PPGKGLEWIG YISYDGTNNY
     61  KPSLKDRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARYG RVFFDYWGQG TLVTVSS

>SEQ_ID_NO_16  (107 letters)
      1  RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD
     61  SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC

>SEQ_ID_NO_17  (330 letters)
      1  ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
     61  GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGG
    121  PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
    181  STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
    241  LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
    301  QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
```

Top publications

All 2 publications, by best query match.

Publication	Published	Applicant	Title	Best query match	Matches
EP 0103960	1984-03-28		DNA sequences coding for the DR beta-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto.	14.3%	2
WO 0121796	2001-03-29		GL50 molecules and uses therefor.	10%	1

Top matches

The first 25 of 3,111 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
2,454	SEQ_ID_NO_16	P01834		1967	100%	100%	100%	5.8e-59
2,766	SEQ_ID_NO_17	P0DOX5		1976	99.4%	99.4%	100%	5.5e-196
2,455	SEQ_ID_NO_16	P0DOX7		1970	99.1%	100%	99.1%	5.1e-58
2,767	SEQ_ID_NO_17	P01857		1970	98.8%	99.4%	99.4%	9.1e-195
2,768	SEQ_ID_NO_17	P01859		1969	89.9%	91.2%	99.4%	1.7e-176
2,769	SEQ_ID_NO_17	P01860		1976	89.7%	81.3%	99.4%	5.9e-176
2,770	SEQ_ID_NO_17	P01861		1970	89%	90.8%	99.1%	1.3e-174
658	SEQ_ID_NO_10	P01599		1973	83.7%	95.8%	88.8%	1.6e-52

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
1,544	SEQ_ID_NO_14	P01631		1983	81%	81.3%	100%	4.6e-53
659	SEQ_ID_NO_10	A0A0C4DH72		2001	77.3%	90.4%	87.9%	6.2e-48
1,545	SEQ_ID_NO_14	A2NJV5		1996	76%	84%	89.3%	3.0e-49
662	SEQ_ID_NO_10	P0DOX7		1970	75.4%	78.5%	100%	2.9e-46
1,546	SEQ_ID_NO_14	P01615		1967	75.1%	86%	89.3%	1.3e-48
661	SEQ_ID_NO_10	P04430		1986	75%	86.3%	88.8%	2.8e-46
660	SEQ_ID_NO_10	A0A075B6S4		2001	75%	85.3%	88.8%	2.8e-46
1,547	SEQ_ID_NO_14	P06310		1985	74%	83%	89.3%	9.7e-48
663	SEQ_ID_NO_10	P01601		1980	73.8%	86.3%	88.8%	2.2e-45
1,548	SEQ_ID_NO_14	A0A075B6S2		2001	73.6%	82%	89.3%	1.7e-47
664	SEQ_ID_NO_10	A0A0C4DH69		2001	73.3%	86.3%	88.8%	5.2e-45
665	SEQ_ID_NO_10	P01611		1980	73.1%	85.3%	88.8%	7.0e-45
666	SEQ_ID_NO_10	A0A0C4DH73		2001	73.1%	85.3%	88.8%	7.0e-45
1,549	SEQ_ID_NO_14	P01630		1983	72.9%	74.1%	100%	5.2e-47
1,550	SEQ_ID_NO_14	A0A075B6S6		2001	72.6%	82%	89.3%	9.9e-47
1	SEQ_ID_NO_6	P01631		1983	72.4%	75%	100%	3.3e-49
1,135	SEQ_ID_NO_11	P01764		1974	72.3%	92.9%	78.4%	1.2e-51

Case log

52 events; every event checks out. Each event's SHA-256 covers the event and the SHA-256 of the one before it, so a change to any event breaks the chain from there on. The table shows each SHA-256's first 12 characters, in the events' words too.

#	When (UTC)	By	Event	SHA-256
1	2026-11-23 23:17	ConductScience	Started the case “US 20260347484 A1: Anti-IGF-1R antibodies and uses thereof”.	`d70b3cd1b67d`
2	2026-11-23 23:17	ConductScience	Imported 17 claims from US 20260347484 A1 as set 1 (as published, 2026-11-05). Claims SHA-256 31097796e595.	`442afc9d0baa`
3	2026-11-23 23:17	ConductScience	The rules (version 1.5.0) found 14 features.	`d86d81bbc010`
4	2026-11-23 23:17	ConductScience	Read 69 paragraphs of the description from US 20260347484 A1, 16 citing a SEQ ID NO. Specification SHA-256 952df018ff1a.	`6b2cf02cda18`
5	2026-11-23 23:17	ConductScience	Set the application number to US 19/664,540, from US 20260347484 A1.	`c936c7a37d94`
6	2026-11-23 23:17	ConductScience	Set the prior art date to 2026-04-30 (filing date), from US 20260347484 A1.	`42bdd8baae77`
7	2026-11-23 23:17	ConductScience	Set the prior art date to 2020-04-10 (earliest priority date).	`b43e29a6e194`
8	2026-11-23 23:17	ConductScience	Accepted F1 in claim 1 (SEQ ID): “SEQ ID NO:6”.	`3460ab25e757`
9	2026-11-23 23:17	ConductScience	Accepted F2 in claim 1 (SEQ ID): “SEQ ID NO:10”.	`8354a8485d44`
10	2026-11-23 23:17	ConductScience	Accepted F3 in claim 1 (SEQ ID): “SEQ ID NO:14”.	`dfa7ee7ad197`
11	2026-11-23 23:17	ConductScience	Accepted F4 in claim 1 (SEQ ID): “SEQ ID NO:7”.	`251b39ac2459`
12	2026-11-23 23:17	ConductScience	Accepted F5 in claim 1 (SEQ ID): “SEQ ID NO:11”.	`c4d7f00761ef`
13	2026-11-23 23:17	ConductScience	Accepted F6 in claim 1 (SEQ ID): “SEQ ID NO:15”.	`34ec71a5a3b2`
14	2026-11-23 23:17	ConductScience	Accepted F7 in claim 1 (SEQ ID): “SEQ ID NO:6”.	`909c7a781e44`
15	2026-11-23 23:17	ConductScience	Accepted F8 in claim 1 (SEQ ID): “SEQ ID NO:7”.	`f91e9c723ce2`
16	2026-11-23 23:17	ConductScience	Accepted F9 in claim 1 (SEQ ID): “SEQ ID NO:10”.	`99a90ff20895`
17	2026-11-23 23:17	ConductScience	Accepted F10 in claim 1 (SEQ ID): “SEQ ID NO:11”.	`09a9a3b22a77`
18	2026-11-23 23:17	ConductScience	Accepted F11 in claim 1 (SEQ ID): “SEQ ID NO:14”.	`9892e0f7aed7`
19	2026-11-23 23:17	ConductScience	Accepted F12 in claim 1 (SEQ ID): “SEQ ID NO:15”.	`c8c7b2fa32bd`
20	2026-11-23 23:17	ConductScience	Accepted F13 in claim 2 (SEQ ID): “SEQ ID NO:16”.	`9a80d4ba67b3`
21	2026-11-23 23:17	ConductScience	Accepted F14 in claim 2 (SEQ ID): “SEQ ID NO:17”.	`8f635847342c`
22	2026-11-23 23:17	ConductScience	Drafted the plan: 2 searches, 0 features not covered.	`71bf5b01a99a`
23	2026-11-23 23:17	ConductScience	Locked plan version 1: 2 searches, 0 features not covered. Plan SHA-256 f778d6703edb.	`5adb6c485ac4`
24	2026-11-23 23:17	ConductScience	Ran P1 and P2 from plan version 1: 2 search jobs.	`d0ad27a0b9b9`
25	2026-11-23 23:22	ConductScience	Chose 5 references for the chart of claim 1.	`255947e391b2`
26	2026-11-23 23:22	ConductScience	Kept publication US 20190153471-A1 of search 41607d0f.	`14b3e070f714`
27	2026-11-23 23:22	ConductScience	Kept publication WO 02053596-A2 of search 41607d0f.	`d321897500b5`
28	2026-11-23 23:22	ConductScience	Kept publication US 20040086503-A1 of search 41607d0f.	`0364285a7ebd`
29	2026-11-23 23:22	ConductScience	Kept publication WO 03059951-A2 of search 41607d0f.	`7b28d2b722c4`
30	2026-11-23 23:22	ConductScience	Kept publication US 20050084906-A1 of search 41607d0f.	`61a5f5eb6f35`

#	When (UTC)	By	Event	SHA-256
31	2026-11-23 23:22	ConductScience	Accepted sentence 1 for publication WO 02053596-A2 of search 41607d0f: “SEQ ID NO: 45 of WO 02053596-A2 matches SEQ ID NO: 11 of claim 1 at 100% identity over 125 of 125 residues (Query Match 100%).”	`d652c6931c1a`
32	2026-11-23 23:22	ConductScience	Accepted sentence 3 for publication WO 02053596-A2 of search 41607d0f: “Published 2002-07-11, before the earliest priority date of 2020-04-10.”	`db56abbae87a`
33	2026-11-23 23:22	ConductScience	Accepted sentence 1 for publication WO 03059951-A2 of search 41607d0f: “SEQ ID NO: 79 of WO 03059951-A2 matches SEQ ID NO: 15 of claim 1 at 100% identity over 117 of 117 residues (Query Match 100%).”	`fa1e5d767f22`
34	2026-11-23 23:22	ConductScience	Accepted sentence 3 for publication WO 03059951-A2 of search 41607d0f: “Published 2003-07-24, before the earliest priority date of 2020-04-10.”	`da27cf7d9862`
35	2026-11-23 23:22	ConductScience	Accepted sentence 1 for publication US 20040086503-A1 of search 41607d0f: “SEQ ID NO: 45 of US 20040086503-A1 matches SEQ ID NO: 11 of claim 1 at 100% identity over 125 of 125 residues (Query Match 100%).”	`f34a93420f41`
36	2026-11-23 23:22	ConductScience	Accepted sentence 3 for publication US 20040086503-A1 of search 41607d0f: “Published 2004-05-06, before the earliest priority date of 2020-04-10.”	`9089ebf0f750`
37	2026-11-23 23:22	ConductScience	Accepted sentence 1 for publication US 20050084906-A1 of search 41607d0f: “SEQ ID NO: 79 of US 20050084906-A1 matches SEQ ID NO: 15 of claim 1 at 100% identity over 117 of 117 residues (Query Match 100%).”	`d250616ff752`
38	2026-11-23 23:22	ConductScience	Accepted sentence 3 for publication US 20050084906-A1 of search 41607d0f: “Published 2005-04-21, before the earliest priority date of 2020-04-10.”	`993e617c19b7`
39	2026-11-23 23:22	ConductScience	Accepted sentence 1 for publication US 20190153471-A1 of search 41607d0f: “SEQ ID NO: 12611 of US 20190153471-A1 matches SEQ ID NO: 17 of claim 2 at 100% identity over 330 of 330 residues (Query Match 100%).”	`de5d50a681a3`
40	2026-11-23 23:22	ConductScience	Accepted sentence 3 for publication US 20190153471-A1 of search 41607d0f: “Published 2019-05-23, before the earliest priority date of 2020-04-10.”	`bed2aef6ab61`
41	2026-11-23 23:22	ConductScience	Accepted the summary of the case, filled in from template conductbiology.summaries.template.case.v1 b65b47e0.	`f9fb9d236c1e`
42	2026-11-23 23:23	ConductScience	Accepted the summary of the results, filled in from template conductbiology.summaries.template.results.v1 91ed1f45.	`f9b0b3bfc313`
43	2026-11-23 23:23	ConductScience	Accepted the summary of search 1, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`32ffe5645bcd`
44	2026-11-23 23:23	ConductScience	Accepted the summary of search 2, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`1b8fe4f9235c`
45	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 6, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`91e88e6cf99f`
46	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 7, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`e11100391db2`

#	When (UTC)	By	Event	SHA-256
47	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 10, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`531144ba8fcd`
48	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 11, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`a33abae764d3`
49	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 14, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`b78255a65ca4`
50	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 15, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`0169ab5d71ae`
51	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 16, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`69ba80a0871e`
52	2026-11-23 23:23	ConductScience	Accepted the summary of SEQ ID NO: 17, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`faa8e29f00c7`